Novo Nordisk's Obesity Drugs Exceed ICER’s Cost Effectiveness Thresholds

Draft Report From Pricing Watchdog Calls Out Wegovy, Saxenda

magnified money
A ICER report is taking a closer look at obesity drug prices • Source: Alamy

More from Drug Pricing

More from Scrip